Mirati Therapeutics Reports Financial Results And Provides Business Update For The Second Quarter 2016

SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) (the Company or Mirati) today reported financial results for the second quarter ended June 30, 2016 and provided an update on its product development programs.

"We reported progress across our pipeline during the second quarter, including clinical responses in patients treated with glesatinib and sitravatinib.  We have since treated a number of patients with the new spray-dried dispersion formulation of glesatinib and have observed improved tolerability compared to the original formulation," said Charles M. Baum, M.D., Ph.D., President and CEO of Mirati.  "Confirming responses to this formulation is our highest priority.  We are encouraged by enrollment rates in this clinical trial as well as our other trials, and will provide efficacy updates for all of our programs as they progress."

Current Programs                                                          

Glesatinib (MGCD265)
The Phase 2 clinical trial in non-small cell lung cancer (NSCLC) patients with MET genetic alterations is currently enrolling patients on the new spray-dried dispersion (SDD) formulation of glesatinib.  Enrollment rates in the trial continue to increase, due in part to the Company's diagnostic partnerships. These have significantly increased the ability to identify and enroll patients and have further confirmed that approximately seven percent of NSCLC patients express the mutations of interest.  To date, the SDD formulation is demonstrating improved tolerability. An update will be provided once data is collected on at least 15 patients.

Sitravatinib (MGCD516) 
The Phase 1b clinical trial of sitravatinib continues to enroll patients with RET, CHR4q12 and CBL genetic alterations in NSCLC and other solid tumors. Patient enrollment is on track, and updates will be provided on the status of this clinical trial as we receive more data.

Mocetinostat (MGCD103)  
The Phase 2 clinical trial for mocetinostat in combination with durvalumab, MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, was initiated in June 2016 and is progressing as planned. The clinical trial is exploring the potential of mocetinostat to enhance the effectiveness of checkpoint inhibitors in NSCLC and other solid tumors.                 

Second Quarter and First Half 2016 Financial Results

Cash, cash equivalents, and short-term investments were $91.3 million at June 30, 2016, compared to $122.3 million at December 31, 2015.

Research and development expenses for the second quarter of 2016 were $18.4 million, compared to $11.3 million for the same period in 2015. Research and development expenses for the six months ended June 30, 2016 were $36.4 million compared to $19.5 million for the same period in 2015.  The increase in research and development expenses for both the three and six months ended June 30, 2016 primarily relates to an increase in expenses associated with ongoing clinical trials, primarily for glesatinib, as well as an increase in other research and development expenses, which reflects both higher compensation costs due to an increase in research and development employees during the three and six months ended June 30, 2016 compared to the same period of 2015, as well as a one-time license fee of $2.5 million related to an early stage discovery project.

General and administrative expenses for the second quarter of 2016 were $3.8 million, compared to $4.2 million for the same period in 2015. General and administrative expenses for the six months ended June 30, 2016 were $7.9 million compared to $8.0 million for the same period of 2015.  The decrease in general and administrative expense for second quarter primarily reflects a decrease in employee-related expense, which was primarily due to a reversal of non-cash stock-based compensation expense associated with unvested stock options granted to our former Chief Operations Officer, partially offset by a non-recurring severance charge associated with his resignation. 

Net loss for the second quarter of 2016 was $22.0 million, or $1.11 per share, compared to net loss of $15.5 million, or $0.95 per share, for the same period in 2015. Net loss for the six months ended June 30, 2016 was $44.0 million, or $2.24 per share, compared to $27.4 million, or $1.74 per share, for the same period of 2015. 

About Mirati Therapeutics

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.  In addition, our product candidates will be evaluated in combination with checkpoint inhibitors (anti-PD1 and PD-L1) to determine whether they will enhance the efficacy of those agents in patients with non-small cell lung cancer ("NSCLC") and other solid tumors. 

To read full press release, please click here.